The outcome of the movement disorder in methcathinone abusers: clinical,MRIand manganesemia changes, and neuropathology

Authors:

Abstract
Background and purpose: There is limited knowledge regarding the long‐term outcome of the methcathinone/manganese‐induced movement disorder. Our purpose was to define prognosis in intravenous methcathinone abusers affected by this distinctive disorder attributed to manganese (Mn) toxicity. Also, neuropathology from a globus pallidus region biopsy from a former user is reported.Methods: Eighteen methcathinone abusers were categorized as active (five), discontinued (four) or former (nine) users. They were reassessed after a median of 32.5 months (range 3.4–59.6) clinically, on rating scales, and withMRIand bloodMn levels. The biopsy was examined ultrastructurally.Results: Overall the group showed a slight tendency to deterioration at follow‐up on clinical assessment of motor functioning, especially the active users. No significant change occurred on parkinsonian rating scale reassessment. Significant reduction inMn levels occurred in former users, and decreasedT1‐weighted hyperintensity on basal gangliaMRIoccurred in 3 of 4 former and 2 of 3 discontinued users, despite lack of clinical improvement. The biopsy consisted of white matter showing decompacted myelin sheaths and frequent abnormalities of mitochondria.Conclusions: No improvement in thisMn‐induced movement disorder occurs after cessation of methcathinone abuse despite improvement ofMn blood levels and/orMRIabnormalities. Ultrastructural abnormalities in a former user confirm structural damage to white matter is associated with the disorder. Methcathinone/Mn toxicity is an important, disabling and permanent medical sequel of intravenous drug abuse in the former Soviet Union.

This publication has 28 references indexed in Scilit: